ClinicalTrials.gg
Not yet recruitingNCT07695922COLERICA IIUpdated Jul 10, 2026

Implementation of RICA (ERAS) Guidelines in Grade II Acute Cholecystitis Undergoing Early Laparoscopic Cholecystectomy

An interventional study of RICA Perioperative Care Pathway in Cholecystitis, Acute, Cholecystectomy, Laparoscopic and Enhanced Recovery After Surgery, sponsored by Hospital d'Igualada. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Hospital d'Igualada · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Cholecystitis, Acute with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Cholecystitis, Acute · Spain.

Started
2026
the only one that year
No phase
5 of 13
5 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Hospital d'Igualada

Among the 13 studies in Cholecystitis, Acute with a site in Spain, this one is the only one that started in 2026, is one of 5 with no phase, and was the 13th registered.

Cholecystitis, Acute

140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.

Browse Cholecystitis, Acute studies →

Open to participants now

7 of the 13 studies in Cholecystitis, Acute with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 21 Cholecystitis, Acute studies recruiting now, 17 (81%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cholecystitis, Acute with a site in Spain, or all of them as a file.
02

Study summary

Background Acute cholecystitis (sudden gallbladder inflammation, usually due to gallstones) is a highly frequent surgical emergency. For patients with moderate disease (Grade II, according to the international Tokyo Guidelines 2018), current standards recommend performing keyhole surgery (early laparoscopic cholecystectomy) within 72 hours of admission or up to 10 days from symptom onset. While the surgical timing is well-defined, care management before, during, and after surgery varies greatly. Standardised care pathways called RICA (Rehabilitación Multimodal en Cirugía del Adulto), which align with global Enhanced Recovery After Surgery (ERAS) protocols, use evidence-based steps to protect body function, reduce pain without heavy opioid use, and help patients walk and eat sooner. Although highly successful in planned surgeries, there is very little specific data or standard pathways regarding the application of these recovery protocols in urgent, complex cases like Grade II acute cholecystitis.

Purpose The main objective of this study is to evaluate the clinical efficiency and safety of implementing a standardized RICA perioperative care pathway in patients with Grade II acute cholecystitis undergoing early laparoscopic cholecystectomy, comparing them against a historical control group treated under conventional care.

Description

This single-centre, non-randomised interventional study uses a quasi-experimental, before-after design at the University Hospital of Igualada. The study will contrast two separate groups of adult patients aged between 18 and 85 years:

  • A historical control cohort (retrospective phase, 2023-2025) consisting of patients who received conventional, non-standardised care.
  • An intervention cohort (prospective phase, 2026-2029) consisting of patients treated strictly according to the new multidisciplinary RICA protocol.

The study aims to demonstrate that standardising care reduces the total postoperative length of hospital stay (measured in hours) without increasing surgical complications or unplanned readmissions. All clinical variables, including patient risks, surgical difficulty scales, complications up to 90 days, and protocol compliance rates, will be securely managed using an institutional REDCap database.

Read the detailed description

Introduction and Clinical Framework

Acute cholecystitis constitutes one of the most prevalent acute surgical conditions managed within emergency departments across Europe. Epidemiological indicators highlight a rising incidence, particularly within the population over 65 years of age. While cholelithiasis affects approximately 10% to 15% of the general adult population, up to 40% of these individuals experience stone-related complications, with acute cholecystitis serving as the primary clinical manifestation in a substantial proportion of symptomatic cases.

The Tokyo Guidelines 2018 (TG18) represent the international gold standard for the diagnosis and severity stratification of this condition. Grade II (moderate) acute cholecystitis is characterised by marked local inflammation that complicates direct surgical management. Diagnostic features for Grade II include a marked leukocytosis (white blood cell count greater than 18,000/mm³), a tender palpable mass in the right upper abdominal quadrant, or a duration of clinical symptoms exceeding 72 hours. It also encompasses advanced local inflammatory findings confirmed via diagnostic imaging, such as gangrenous, emphysematous, or pericolecystic abscess formations, hepatic abscesses, or biliary peritonitis.

The seminal multi-centre randomised controlled trial (ACDC study) established the clinical superiority of early laparoscopic cholecystectomy over conservative management followed by delayed elective surgery, showing significant reductions in patient morbidity, hospital stay, and resource utilization. Current consensus guidelines from the World Society of Emergency Surgery (WSES) define early cholecystectomy as an intervention performed within 7 days of hospital admission or up to 10 days from the onset of clinical symptoms. While the technical advantages of early surgery in Grade II cases are recognised-offering a viable laparoscopic window before tissue fibrosis sets in-there is a critical lack of standardized perioperative management frameworks tailored specifically for this urgent, moderately severe cohort, as most general Enhanced Recovery After Surgery (ERAS) data originates from elective colorectal or mild (Grade I) cholecystitis pathways.

Study Objectives and Hypotheses

The primary objective of this study is to evaluate the clinical efficiency and recovery optimization of an institutional RICA protocol implementation for TG18 Grade II acute cholecystitis managed via early laparoscopic cholecystectomy. The core hypothesis is that the systematic and multi-professional standardisation of care will significantly reduce the postoperative length of hospital stay (measured precisely in hours) without increasing overall 90-day postoperative morbidity or unplanned hospital readmissions.

The secondary objectives are:

  1. To compare baseline characteristics and clinical outcomes between the intervention group and historical controls to assess protocol impact.
  2. To monitor perioperative morbidity by tracking the incidence and severity of surgical complications using the Clavien-Dindo classification up to 90 days postoperatively.
  3. To determine the rate and underlying causes of unplanned hospital readmissions within a 90-day postoperative window.

Methodology and Work Plan

This investigation employs a quasi-experimental, single-centre, before-after cohort design conducted at the University Hospital of Igualada (Catalonia, Spain). The study architecture is divided into two sequential chronological periods:

  • The Retrospective Phase (Historical Control Group, January 2023 - December 2025): Medical records of consecutive patients matching the inclusion criteria who underwent conventional surgical and perioperative care will be reviewed to establish a robust baseline.
  • The Prospective Phase (Intervention Group, March 2026 - February 2029): Consecutive patients will be prospectively enrolled, providing written informed consent, and managed strictly in accordance with the multidisciplinary RICA care matrix.

The project timeline dictates a one-week formal introduction to brief and align the departments of General Surgery, Anaesthesiology, and Emergency and Wards Nursing, alongside the deployment of the REDCap data infrastructure. The inclusion and data capture phase spans 36 months, followed by a 6-month data cleaning, 90-day follow-up completion, and final statistical analysis phase. The final 6 months are dedicated to scientific manuscript preparation following the TREND (Transparent Reporting of Evaluations with Nonrandomized Designs) statement guidelines.

The RICA Perioperative Care Matrix

The active intervention evaluated in this study replaces conventional practitioner-dependent management with a highly structured, time-sequenced multimodal care pathway involving surgeons, anaesthetists, and specialised nursing staff. The protocol is structured as follows:

  1. Preoperative Stage: Includes point-of-care ultrasound (POCUS) clinical assessment; systematic evaluation of surgical risk and patient frailty using validated clinical frailty scores; strict glycaemic control aiming to maintain blood glucose below 180 mg/dL; targeted antimicrobial prophylaxis governed by hospital antibiotic stewardship guidelines (PROA); active thermal management using forced-air warming blankets for vulnerable or frail individuals; and targeted patient education detailing early recovery objectives.
  2. Intraoperative Stage: Use of the surgical safety checklist; routine advanced monitoring; execution of standard or subtotal laparoscopic cholecystectomy (documenting fenestrated or reconstituted approaches, or conversion to open surgery); rapid sequence anaesthetic induction; controlled hyperoxia ($FiO_2$ 0.6 to 0.8); goal-directed fluid therapy (utilising non-invasive advanced haemodynamic monitoring systems like Clearsight) or weight-adjusted restrictive fluid administration (3-5 mL/kg/h); mandatory core normothermia maintenance; strict restriction of routine nasogastric tubes, urinary catheters, or abdominal drainage placement; and the mandatory application of opioid-sparing multimodal analgesia via local wound infiltration or Transversus Abdominis Plane (TAP) blocks.
  3. Immediate Postoperative Stage (Day 0): Continued active warming; oxygen therapy adjusted to blood oxygen saturation; multimodal non-opioid analgesia restricting morphic rescue doses; restrictive fluid maintenance; early mobilization protocol requiring sitting within 2 hours and active ambulation within 8 hours post-surgery; and early oral intake initiation (clear fluids) within 6 to 8 hours of the procedure.
  4. Postoperative Day 1: Progression to a liquid diet; active ambulation and targeted respiratory physiotherapy; transition to oral analgesia; discontinuation of intravenous fluid lines upon adequate oral tolerance; and initial evaluation for the removal of any intraoperatively placed drains or catheters.
  5. Postoperative Day 2 \& Extended Stay: Advancement to a progressive low-fat biliary diet; full independent ambulation; continued oral analgesia and PROA-aligned antibiotic therapy; and daily formal assessment against discharge criteria.
  6. Discharge and Follow-up Criteria: Discharge is authorized only when the patient meets all standard criteria: absence of fever, adequate pain control via oral analgesia, complete independent ambulation, active patient acceptance, and a pre-discharge objective laboratory check measuring C-Reactive Protein (CRP) and liver function enzymes. Post-discharge care includes an institutional 24-hour telephone follow-up call, coordinated continuity with primary care medical teams, and a formal clinical follow-up assessment at 3 to 4 weeks.

Advanced Statistical Analysis Strategy

All data management will be executed utilizing the REDCap platform. Statistical computing will be performed using R software (version 4.3 or higher), with a fixed significance threshold of $p \< 0.05$. Continuous variables will be evaluated for normality via the Shapiro-Wilk test and expressed as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical variables will be analysed using Chi-squared or Fisher's exact tests.

To evaluate the primary outcome (postoperative length of stay in hours), a multivariable linear regression model will be constructed. The dependent variable will be the log-transformed length of stay to account for non-normal distributions, with group allocation (RICA pathway vs. conventional care) serving as the main independent predictor. The model will be adjusted for key baseline covariates exhibiting unbalance, alongside established clinical confounders including age, ASA physical status, clinical frailty score, comorbidities, and initial biochemical severity indicators.

To account for the inherent selection bias of a non-randomised before-after design and mitigate period-related confounding, an advanced sensitivity analysis using Propensity Score Matching (PSM) will be implemented. Propensity scores will be calculated for each patient via a logistic regression model incorporating baseline demographics and clinical risks. Patients from the historical and prospective cohorts will be matched using a 1:1 nearest-neighbour algorithm, creating a balanced sub-cohort to isolate the true therapeutic effect of the RICA intervention.

Furthermore, a Cox proportional hazards regression model will be deployed to evaluate the time-to-discharge rate, treating the hospital discharge as the event of interest, complemented by Kaplan-Meier survival curves. To prove causal association, an institutional compliance index (0% to 100%) will be calculated for each intervention patient based on the percentage of RICA items fulfilled; a linear regression will test the direct correlation between high protocol adherence and reduced hospital stay. For the safety endpoint (Clavien-Dindo complications $\ge$ II), a formal non-inferiority analysis will be performed, applying a pre-specified safety margin of 5% to confirm that the RICA pathway does not compromise patient safety. Missing data patterns will be checked; if random and under 5%, complete-case analysis will be used, otherwise multiple imputation techniques will be applied.

03

Conditions studied

  • Cholecystitis, Acute
  • Cholecystectomy, Laparoscopic
  • Enhanced Recovery After Surgery

Browse trials for

Keywords

  • Acute cholecystitis
  • Laparoscopic cholecystectomy
  • Enhanced recovery after surgery
  • Clinical pathways
  • Perioperative care
  • Emergency surgery
  • Tokyo Guidelines
  • Length of hospital stay
  • Quasi-experimental study
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 85 years, inclusive.
  • Confirmed diagnosis of Grade II (moderate) acute cholecystitis based on the Tokyo Guidelines 2018 (TG18) criteria.
  • Patients scheduled for laparoscopic cholecystectomy within 72 hours of hospital admission and up to 10 days from symptom onset.
  • (ASA) physical status classification of I, II, or III.

Exclusion criteria

Exclusion Criteria:

  • Ongoing therapeutic anticoagulation or dual antiplatelet therapy that cannot be safely suspended or modified for surgery.
  • Concurrent advanced chronic liver disease ( class B or C), severe acute biliary pancreatitis, or associated complex biliary tract pathology.
  • Active SARS-CoV-2 (COVID-19) infection confirmed by polymerase chain reaction (PCR).
  • Refusal or inability to provide written for the prospective phase of the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    RICA Pathway

    Prospective cohort of patients diagnosed with Tokyo Guidelines 2018 (TG18) Grade II acute cholecystitis managed prospectively between March 2026 and February 2029. Participants in this arm undergo early laparoscopic cholecystectomy within 72 hours of admission and are treated strictly according to the institutional multidisciplinary RICA (Rehabilitación Multimodal en Cirugía del Adulto) pathway. This evidence-based care bundle integrates pre-emptive frailty screening, restricted fasting windows, targeted point-of-care ultrasound (POCUS), strict perioperative glycaemic control (\< 180 mg/dL), intraoperative goal-directed fluid therapy, mandatory maintenance of core normothermia, systematic avoidance of routine abdominal drains, and opioid-sparing multimodal analgesia (including abdominal wall blocks). Postoperative care dictates early mobilisation within 8 hours and early oral intake within 6 to 8 hours of surgery.

    Other: RICA Perioperative Care Pathway

  • No intervention
    Conventional Care

    Retrospective historical control cohort comprising patients diagnosed with Tokyo Guidelines 2018 (TG18) Grade II acute cholecystitis who underwent early laparoscopic cholecystectomy at the same institution between January 2023 and December 2025. Participants in this arm were managed under conventional, non-standardised perioperative care practices prior to the formal clinical implementation of the RICA pathway. Clinical decisions regarding preoperative fasting duration, intraoperative fluid management, routine placement of abdominal drains, nasogastric tubes, or urinary catheters, types of intraoperative analgesia (including reliance on systemic opioids), and milestones for postoperative mobilization and oral intake progression were dependent on individual practitioner preference and standard ward routines.

Interventions

  • OtherRICA Perioperative Care Pathway

    A standardized, multidisciplinary, evidence-based clinical pathway designed to optimize perioperative recovery for patients undergoing emergency laparoscopic cholecystectomy for Grade II acute cholecystitis. The intervention replaces conventional practitioner-dependent care with a highly structured time-matrix protocol including: preoperative point-of-care ultrasound (POCUS), frailty screening, restricted fasting windows, strict glycaemic control (\<180 mg/dL), and antimicrobial stewardship; intraoperative goal-directed fluid therapy, mandatory core normothermia maintenance, restricted use of routine abdominal drains/catheters, and opioid-sparing multimodal analgesia (abdominal wall blocks); and postoperative early mobilization (within 8 hours), early oral intake (within 6 to 8 hours), and standardized multi-professional discharge criteria checking.

06

What researchers measure

Primary outcomes

  1. Postoperative Length of Hospital Stay

    The total duration of hospitalisation calculated in hours, measured from the exact time of the completion of the laparoscopic cholecystectomy (skin closure) until the exact time of formal hospital discharge.

    Time frame: From the time of surgery completion up to formal hospital discharge (estimated up to 90 days postoperatively).

Secondary outcomes

  1. Postoperative Morbidity Rate

    Incidence and severity of complications occurring after surgery, graded according to the international Clavien-Dindo classification. The primary safety focus will be on significant complications classified as Grade II or higher (Clavien-Dindo $\\ge$ II), which include infections requiring specific antimicrobial therapies, leaks, or collections requiring intervention.

    Time frame: Up to 90 days postoperatively.

  2. Unplanned Hospital Readmission Rate

    The percentage of patients requiring any unplanned or emergency hospital readmission related to the primary surgical condition, surgical site complications (such as intra-abdominal collections, surgical site infections, or biliary leaks), or systemic medical complications secondary to the intervention.

    Time frame: Up to 90 days post-discharge.

  3. RICA Protocol Adherence Index

    An institutional compliance score calculated as the percentage of implemented RICA protocol care items successfully fulfilled for each patient out of the total applicable items across the preoperative, intraoperative, and postoperative care matrix (expressed as a continuous scale from 0% to 100%).

    Time frame: From hospital admission up to formal hospital discharge (estimated up to 7 days).

07

Study locations

1 site
  • Hospital Universitari d'Igualada
    Igualada, Barcelona 08700, Spain
    • Cristina Pozo Salgado, MSc · Contactcpozo@csa.cat · +34666441852
    • Marta Banque Navarro, PhD · Contactmbanque@csa.cat · +34938075585
    • Xavier Viñas Trullen, MD · Sub investigator
08

References and documents

Publications

  • Demouron M, Selvy M, Dembinski J, Mauvais F, Cheynel N, Slim K, Sabbagh C, Regimbeau JM. Feasibility and Effectiveness of an Enhanced Recovery Program after Early Cholecystectomy for Acute Calculous Cholecystitis: A 2-Step Study. J Am Coll Surg. 2022 May 1;234(5):840-848. doi: 10.1097/XCS.0000000000000123. PubMed 35426396 ↗
  • Wakabayashi G, Iwashita Y, Hibi T, Takada T, Strasberg SM, Asbun HJ, Endo I, Umezawa A, Asai K, Suzuki K, Mori Y, Okamoto K, Pitt HA, Han HS, Hwang TL, Yoon YS, Yoon DS, Choi IS, Huang WS, Gimenez ME, Garden OJ, Gouma DJ, Belli G, Dervenis C, Jagannath P, Chan ACW, Lau WY, Liu KH, Su CH, Misawa T, Nakamura M, Horiguchi A, Tagaya N, Fujioka S, Higuchi R, Shikata S, Noguchi Y, Ukai T, Yokoe M, Cherqui D, Honda G, Sugioka A, de Santibanes E, Supe AN, Tokumura H, Kimura T, Yoshida M, Mayumi T, Kitano S, Inomata M, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: surgical management of acute cholecystitis: safe steps in laparoscopic cholecystectomy for acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):73-86. doi: 10.1002/jhbp.517. Epub 2018 Jan 10. PubMed 29095575 ↗
  • Ripolles-Melchor J, Ramirez-Rodriguez JM, Casans-Frances R, Aldecoa C, Abad-Motos A, Logrono-Egea M, Garcia-Erce JA, Camps-Cervantes A, Ferrando-Ortola C, Suarez de la Rica A, Cuellar-Martinez A, Marmana-Mezquita S, Abad-Gurumeta A, Calvo-Vecino JM; POWER Study Investigators Group for the Spanish Perioperative Audit and Research Network (REDGERM). Association Between Use of Enhanced Recovery After Surgery Protocol and Postoperative Complications in Colorectal Surgery: The Postoperative Outcomes Within Enhanced Recovery After Surgery Protocol (POWER) Study. JAMA Surg. 2019 Aug 1;154(8):725-736. doi: 10.1001/jamasurg.2019.0995. PubMed 31066889 ↗
  • Gustafsson UO, Hausel J, Thorell A, Ljungqvist O, Soop M, Nygren J; Enhanced Recovery After Surgery Study Group. Adherence to the enhanced recovery after surgery protocol and outcomes after colorectal cancer surgery. Arch Surg. 2011 May;146(5):571-7. doi: 10.1001/archsurg.2010.309. Epub 2011 Jan 17. PubMed 21242424 ↗
  • Paton F, Chambers D, Wilson P, Eastwood A, Craig D, Fox D, Jayne D, McGinnes E. Effectiveness and implementation of enhanced recovery after surgery programmes: a rapid evidence synthesis. BMJ Open. 2014 Jul 22;4(7):e005015. doi: 10.1136/bmjopen-2014-005015. PubMed 25052168 ↗
  • Miller TE, Thacker JK, White WD, Mantyh C, Migaly J, Jin J, Roche AM, Eisenstein EL, Edwards R, Anstrom KJ, Moon RE, Gan TJ; Enhanced Recovery Study Group. Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg. 2014 May;118(5):1052-61. doi: 10.1213/ANE.0000000000000206. PubMed 24781574 ↗
  • Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials. Clin Nutr. 2010 Aug;29(4):434-40. doi: 10.1016/j.clnu.2010.01.004. Epub 2010 Jan 29. PubMed 20116145 ↗
  • Ljungqvist O, Nygren J, Thorell A. Modulation of post-operative insulin resistance by pre-operative carbohydrate loading. Proc Nutr Soc. 2002 Aug;61(3):329-36. doi: 10.1079/PNS2002168. PubMed 12230794 ↗
  • Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg. 1995 Jan;180(1):101-25. No abstract available. PubMed 8000648 ↗
  • Griffiths EA, Hodson J, Vohra RS, Marriott P; CholeS Study Group; Katbeh T, Zino S, Nassar AHM; West Midlands Research Collaborative. Utilisation of an operative difficulty grading scale for laparoscopic cholecystectomy. Surg Endosc. 2019 Jan;33(1):110-121. doi: 10.1007/s00464-018-6281-2. Epub 2018 Jun 28. PubMed 29956029 ↗
  • Loozen CS, van Ramshorst B, van Santvoort HC, Boerma D. Early Cholecystectomy for Acute Cholecystitis in the Elderly Population: A Systematic Review and Meta-Analysis. Dig Surg. 2017;34(5):371-379. doi: 10.1159/000455241. Epub 2017 Jan 18. PubMed 28095385 ↗
  • Ugarte-Sierra B, Landaluce-Olavarria A, Cabrera-Serna I, Vinas-Trullen X, Brugiotti C, Ramirez-Rodriguez JM, Arroyo A. Enhanced Recovery After Emergency Surgery: Utopia or Reality? Cir Esp (Engl Ed). 2021 Apr;99(4):258-266. doi: 10.1016/j.ciresp.2020.04.017. Epub 2020 Jun 10. English, Spanish. PubMed 32532473 ↗
  • Qin J, Gou LY, Zhang W, Pu X, Zhang P. Enhanced Recovery After Surgery versus Conventional Care in Cholecystectomy: A Systematic Review and Meta-Analysis. J Laparoendosc Adv Surg Tech A. 2024 Aug;34(8):710-720. doi: 10.1089/lap.2024.0119. Epub 2024 Jul 8. PubMed 38976496 ↗
  • Nassar A, Elshahat I, Forsyth K, Shaikh S, Ghazanfar M. Outcome of early cholecystectomy compared to percutaneous drainage of gallbladder and delayed cholecystectomy for patients with acute cholecystitis: systematic review and meta-analysis. HPB (Oxford). 2022 Oct;24(10):1622-1633. doi: 10.1016/j.hpb.2022.04.010. Epub 2022 May 6. PubMed 35597717 ↗
  • Gutt CN, Encke J, Koninger J, Harnoss JC, Weigand K, Kipfmuller K, Schunter O, Gotze T, Golling MT, Menges M, Klar E, Feilhauer K, Zoller WG, Ridwelski K, Ackmann S, Baron A, Schon MR, Seitz HK, Daniel D, Stremmel W, Buchler MW. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). Ann Surg. 2013 Sep;258(3):385-93. doi: 10.1097/SLA.0b013e3182a1599b. PubMed 24022431 ↗
  • Meyer AE, Pfeiffer CA, Brooks KE, Spate LD, Benne JA, Cecil R, Samuel MS, Murphy CN, Behura S, McLean MK, Ciernia LA, Smith MF, Whitworth KM, Wells KD, Spencer TE, Prather RS, Geisert RD. New perspective on conceptus estrogens in maternal recognition and pregnancy establishment in the pigdagger. Biol Reprod. 2019 Jul 1;101(1):148-161. doi: 10.1093/biolre/ioz058. PubMed 31066888 ↗
  • Nguyen KT, Marsh JW, Tsung A, Steel JJ, Gamblin TC, Geller DA. Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal. Arch Surg. 2011 Mar;146(3):348-56. doi: 10.1001/archsurg.2010.248. Epub 2010 Nov 15. PubMed 21079109 ↗
  • Spanjersberg WR, Reurings J, Keus F, van Laarhoven CJ. Fast track surgery versus conventional recovery strategies for colorectal surgery. Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD007635. doi: 10.1002/14651858.CD007635.pub2. PubMed 21328298 ↗
  • Arenas DL, Viduani A, Bassols AMS, Hauck S. Work From Home or Bring Home the Work? Burnout and Procrastination in Brazilian Workers During the COVID-19 Pandemic. J Occup Environ Med. 2022 May 1;64(5):e333-e339. doi: 10.1097/JOM.0000000000002526. Epub 2022 Feb 24. PubMed 35213483 ↗
  • Zhuang CL, Ye XZ, Zhang XD, Chen BC, Yu Z. Enhanced recovery after surgery programs versus traditional care for colorectal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum. 2013 May;56(5):667-78. doi: 10.1097/DCR.0b013e3182812842. PubMed 23575408 ↗
  • Roulin D, Donadini A, Gander S, Griesser AC, Blanc C, Hubner M, Schafer M, Demartines N. Cost-effectiveness of the implementation of an enhanced recovery protocol for colorectal surgery. Br J Surg. 2013 Jul;100(8):1108-14. doi: 10.1002/bjs.9184. PubMed 23754650 ↗
  • Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg. 2008 Aug;248(2):189-98. doi: 10.1097/SLA.0b013e31817f2c1a. PubMed 18650627 ↗
  • Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051. PubMed 16129869 ↗
  • Ansaloni L, Pisano M, Coccolini F, Peitzmann AB, Fingerhut A, Catena F, Agresta F, Allegri A, Bailey I, Balogh ZJ, Bendinelli C, Biffl W, Bonavina L, Borzellino G, Brunetti F, Burlew CC, Camapanelli G, Campanile FC, Ceresoli M, Chiara O, Civil I, Coimbra R, De Moya M, Di Saverio S, Fraga GP, Gupta S, Kashuk J, Kelly MD, Koka V, Jeekel H, Latifi R, Leppaniemi A, Maier RV, Marzi I, Moore F, Piazzalunga D, Sakakushev B, Sartelli M, Scalea T, Stahel PF, Taviloglu K, Tugnoli G, Uraneus S, Velmahos GC, Wani I, Weber DG, Viale P, Sugrue M, Ivatury R, Kluger Y, Gurusamy KS, Moore EE. 2016 WSES guidelines on acute calculous cholecystitis. World J Emerg Surg. 2016 Jun 14;11:25. doi: 10.1186/s13017-016-0082-5. eCollection 2016. PubMed 27307785 ↗
  • Thiele RH, Rea KM, Turrentine FE, Friel CM, Hassinger TE, McMurry TL, Goudreau BJ, Umapathi BA, Kron IL, Sawyer RG, Hedrick TL. Standardization of care: impact of an enhanced recovery protocol on length of stay, complications, and direct costs after colorectal surgery. J Am Coll Surg. 2015 Apr;220(4):430-43. doi: 10.1016/j.jamcollsurg.2014.12.042. Epub 2015 Jan 9. PubMed 25797725 ↗
  • Gomes CA, Junior CS, Di Saverio S, Sartelli M, Kelly MD, Gomes CC, Gomes FC, Correa LD, Alves CB, Guimaraes SF. Acute calculous cholecystitis: Review of current best practices. World J Gastrointest Surg. 2017 May 27;9(5):118-126. doi: 10.4240/wjgs.v9.i5.118. PubMed 28603584 ↗
  • Tsuyumu M, Tsurumoto T, Iimura J, Nakajima T, Kojima H. Response to a letter to the editor titled, "Weight loss in patients with obstructive sleep apnea: an interventional procedure". Sleep Breath. 2021 Jun;25(2):1165-1166. doi: 10.1007/s11325-020-02154-6. Epub 2020 Oct 28. No abstract available. PubMed 33113071 ↗
  • Li N, Yang F, Zhao Z, Jiang J, Lei Y. Efficacy and safety of Naoxintong capsule for acute ischemic stroke: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021 Aug 27;100(34):e27120. doi: 10.1097/MD.0000000000027120. PubMed 34449516 ↗
  • Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, Rockall TA, Young-Fadok TM, Hill AG, Soop M, de Boer HD, Urman RD, Chang GJ, Fichera A, Kessler H, Grass F, Whang EE, Fawcett WJ, Carli F, Lobo DN, Rollins KE, Balfour A, Baldini G, Riedel B, Ljungqvist O. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS(R)) Society Recommendations: 2018. World J Surg. 2019 Mar;43(3):659-695. doi: 10.1007/s00268-018-4844-y. PubMed 30426190 ↗
  • Yokoe M, Hata J, Takada T, Strasberg SM, Asbun HJ, Wakabayashi G, Kozaka K, Endo I, Deziel DJ, Miura F, Okamoto K, Hwang TL, Huang WS, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Noguchi Y, Shikata S, Ukai T, Higuchi R, Gabata T, Mori Y, Iwashita Y, Hibi T, Jagannath P, Jonas E, Liau KH, Dervenis C, Gouma DJ, Cherqui D, Belli G, Garden OJ, Gimenez ME, de Santibanes E, Suzuki K, Umezawa A, Supe AN, Pitt HA, Singh H, Chan ACW, Lau WY, Teoh AYB, Honda G, Sugioka A, Asai K, Gomi H, Itoi T, Kiriyama S, Yoshida M, Mayumi T, Matsumura N, Tokumura H, Kitano S, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54. doi: 10.1002/jhbp.515. Epub 2018 Jan 9. PubMed 29032636 ↗
  • Pisano M, Allievi N, Gurusamy K, Borzellino G, Cimbanassi S, Boerna D, Coccolini F, Tufo A, Di Martino M, Leung J, Sartelli M, Ceresoli M, Maier RV, Poiasina E, De Angelis N, Magnone S, Fugazzola P, Paolillo C, Coimbra R, Di Saverio S, De Simone B, Weber DG, Sakakushev BE, Lucianetti A, Kirkpatrick AW, Fraga GP, Wani I, Biffl WL, Chiara O, Abu-Zidan F, Moore EE, Leppaniemi A, Kluger Y, Catena F, Ansaloni L. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitis. World J Emerg Surg. 2020 Nov 5;15(1):61. doi: 10.1186/s13017-020-00336-x. PubMed 33153472 ↗

Related links

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be publicly shared due to explicit legal restrictions stipulated in the patient informed consent form approved by the institutional ethics committee. The approved protocol restricts data access strictly to the primary research team and its authorized internal collaborators to ensure compliance with the General Data Protection Regulation (GDPR) and national data protection laws. However, aggregate data and specific methodological details will be fully available in the final publication.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Feb 2029, 31 months later.

Of 43 non-industry interventional studies with no phase under Cholecystitis, Acute, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 31 months is above that.

Counting every sponsor, half of 46 studies reached it within 20 months; a quarter within 9 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartEst.
Jul 10, 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
Apr 1, 2029
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07695922
Lead sponsor
Hospital d'Igualada
Collaborators
Consorci Sanitari de l'Anoia
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 10, 2026 (estimated)
Primary completion
Feb 28, 2029 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Jul 10, 2026

Study contacts

Cesar Alejandro Anaya Romo, MD
Contact
aanaya@csa.cat
+34680523403
Cesar Alejandro Anaya Romo, MD
principal investigator · Consorci Sanitari de l'Anoia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion